

Oct 27, 2017

Version 2

Elevated Histamine Model: A Protocol for an ex vivo model for in vitro study of histamine effect on placenta V.2

DOI

<https://dx.doi.org/10.17504/protocols.io.jigckbw>

Obed Brew¹, Mark HF Sullivan²

¹University of West London, Paragon House, Boston Manor Road, Brentford, Middlesex, United Kingdom;

²Institute of Reproductive & Developmental Biology, Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London, United Kingdom



Obed Brew

Create & collaborate more with a free account

Edit and publish protocols, collaborate in communities, share insights through comments, and track progress with run records.

Create free account

OPEN  ACCESS



DOI: <https://dx.doi.org/10.17504/protocols.io.jigckbw>

Protocol Citation: Obed Brew, Mark HF Sullivan 2017. Elevated Histamine Model: A Protocol for an ex vivo model for in vitro study of histamine effect on placenta. **protocols.io** <https://dx.doi.org/10.17504/protocols.io.jigckbw>

License: This is an open access protocol distributed under the terms of the **Creative Commons Attribution License**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working

Created: August 23, 2017

Last Modified: February 04, 2018

Protocol Integer ID: 7464

Keywords: placenta maternal plasma histamine levels in normal pregnancy, elevated maternal blood histamine, limited changes in maternal blood histamine, maternal blood histamine, elevated levels of histamine, study of histamine effect, histamine level, elevated histamine model, effects of histamine, major source of histamine, endogenous production of histamine, histamine effect, defective histamine, placenta maternal plasma, normal placentae with nhda, normal histamine, histamine, placenta in normal pregnancy, normal placentae, human placenta, placenta, complicated placentae with dhda, deported placental dao activity in maternal blood, complicated placentae, complications of pregnancy, 3rd trimester, first trimester, maternal circulation, aminoguanidine in the dhda sample, maternal blood, active diamine amine oxidase, pregnancy, deported placental dao activity, pregnancy proceed, aminoguanidine, elevated level, fold during normal pregnancy, normal pregnancy, gestational week, spontaneous abortion

Abstract

Maternal plasma histamine levels in normal pregnancy are generally similar to those in non-pregnant women during the first trimester, and usually decline gradually during the 2nd and 3rd trimesters (Brew and Sullivan, 2006). In some complications of pregnancy such as *hyperemesis gravidarum* (HG), spontaneous abortion (SA), pre-term labour (PL) and Pre-eclampsia (PE) histamine levels increase as pregnancy proceeds (Southren *et al.*, 1966; Achari, Achari and Rao, 1971; Beaven *et al.*, 1975), and the elevated levels of histamine may directly cause some of the features of these disorders (Brew and Sullivan, 2006).

Placenta is a major source of histamine, but it also releases active diamine amine oxidase (DAO; EC 1.4.3.22) into the maternal circulation, which metabolises histamine (Kapeller-Adler, 1944; Gunther and Glick, 1967; Semeniuchenko, 1975; Granerus, Gillbrand and Wetterqvist, 1977; Purcell and Hanahoe, 1991; Brew, Lakasing and Sullivan, 2007). This breaks down the histamine released from the placenta in normal pregnancy, leading to the limited changes in maternal blood histamine. Clinically, the deported placental DAO activity in maternal blood increases a 1000 fold during normal pregnancy (Southren *et al.*, 1966).

The DAO activity rises exponentially in the first 24 weeks of normal gestation and plateaus thereafter to form a normal histamine-DAO-axis (nHDA) (Southren *et al.*, 1966; Beaven *et al.*, 1975; Dubois *et al.*, 1977) (Ahlmarm, 1944; Southren *et al.*, 1966; Gunther and Glick, 1967; Weingold and Southren, 1968; Tufvesson, 1978; Beaven *et al.*, 1975; Dubois *et al.*, 1977). In contrast, the spontaneous exponential rise of DAO activity is abrogated from gestational week 8 onwards thus, leading to a defective Histamine-DAO-Axis (dHDA) in pregnancies that present with elevated maternal blood histamine (Southren *et al.*, 1966; Achari, Achari and Rao, 1971; Beaven *et al.*, 1975; Legge and Duff, 1981). *Ex-vivo* defective Histamine-DAO-Axis also referred to Elevated Histamine Model (EHM) was developed to mimic *in vivo* dHDA to study effects of histamine in human placenta. The EHM was developed by creating *in vitro* culture model to represent normal placentae with nHDA and complicated placentae with dHDA. In the nHDA samples, the endogenous DAO activity is maintained to eliminate endogenous production of histamine, while DAO activity is blocked with aminoguanidine in the dHDA samples to allow histamine levels to elevate during the treatment period. Aminoguanidine is a specific inhibitor of DAO enzyme activity (Tamura *et al.*, 1989).



Guidelines

Note:

Syncytiotrophoblast degeneration starts within 24 hours of explant culture and peaks by 48 hours.

Syncytiotrophoblast regeneration is established by 120 hours of culture. Therefore culture explants for 5 days and apply elevated histamine treatment thereafter for a further 24 hours.

Explants cultured for 48 hours produced extremely poor quality RNA for high throughput downstream analysis.

Micro explants incubated at the bottom of the well was associated with decreased explant viability and poor RNA quality.

Human Placental Tissue Collection and Preparation

- 1 Obtain ethics permission and patient consent prior to placental collection.
- 2 Record clinical characteristics of pregnancies for placentae to be studied as Table 1 (sample Table 1 available from http://www.elsevier.com/_data/promis_misc/YPLAC%20Guide%20for%20authors%20Table%201.doc).
- 3 Collect from operating theatre term (38-39 weeks of gestation) placenta delivered by caesarean section from normal pregnancy.
- 4 Inspect the placenta and record evidence for gross abnormalities such as placental infarcts, excessive tears, necrosis, absent cotyledons, discolorations on the maternal and fetal surfaces, and anomalies in cord insertion.
- 5 Cut 2 cm³ of placental samples randomly from at least 3 different healthy looking sampling sites about 5 cm away from the umbilical cord with sterile sharp scissors.
- 6 Excise each sample to include an intact chorionic plate, intervillous space, basal plate and decidua.
- 7 Wash each placental sample in phosphate-buffered saline (PBS) solution (pH 7.4) containing 10% penicillin, streptomycin and L-glutamine (Sigma) to remove excess blood and blood clots.
- 8 Transport each washed sample in 150 mL sterile pots containing warm PBS with 10% penicillin, streptomycin and L-glutamine immediately to the laboratory.
- 9 Aseptically dissect micro explants (<50 mg wet weight) of villous tissue with sterile scalpel from each sample.
- 10 Incubate the micro explant within 30 min of delivery.

Standard Culture

- 11 Place each fragmented micro explant on a mesh support in a 12-well culture plate containing 15mm diameter Netwell inserts with 74µm polyester mesh bottoms attached to polystyrene inserts (Corning, UK).



- 12 Add basic media: RPMI 1640 culture medium (Invitrogen, UK) supplemented with 2 mM L-glutamine, 10% fetal bovine serum, 100 IU/ml penicillin and 100 µg/ml streptomycin.
- 13 Incubate micro explants in basic media at the liquid-gas interface in 8% oxygen and 5% CO₂, at 37°C for 5 days. Note: culture at the bottom of the well was associated with decreased explant viability and poor RNA quality.
- 14 Replace culture media at days 2 and 4: place the media in a sterile container and expose to 8% oxygen tension for 2 hours before the medium change is done. Keep the time for the change of medium to the minimum (less than 5 minutes).

Elevated Histamine Culture

- 15 To create the elevated histamine model, repeat media change on day 5 for elevated histamine treatment:
 1. Replace media for samples designated as dHDA samples with final media containing 100nM histamine in the presence of aminoguanidine (10⁻⁴ M final concentration)
 2. Replace media for samples designated as nHDA with final basic media without aminoguanidine or histamine.
 3. Culture samples for further 24 hours
- 16 At the end of the 6 days culture period collect the explants and store immediately in RNeasy Lysis Buffer (Qiagen) at -80°C.
- 17 Store pre-culture, 0 h control samples obtained from fresh placentae in RNeasy Lysis Buffer at -80°C within 30 minutes of delivery.